An Open-Label, Multi-Center, Single-Arm Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

This project is being done to evaluate the safety and tolerability of glofitamab-polatuzumab-R-CHP in patients newly diagnosed DLBCL and determine if a blood test that measures MRD can identify patients most likely to benefit from this regimen.